Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
| ▸ | CCR3 | P51677 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4932481 | 1.00 | GPR3 (0.38) | GPR3GABRA1GABRB2CCR3KDM4E | |
| SCHEMBL4933768 | 0.78 | GPR3 (0.41) | GPR3KDM4EMEN1ALDH1A1LMNA | |
| SCHEMBL29748388 | 0.78 | GPR3 (0.41) | GPR3KDM4EMEN1ALDH1A1LMNA | |
| SCHEMBL12037326 | 0.78 | GPR3 (0.41) | GPR3KDM4EMEN1ALDH1A1LMNA | |
| SCHEMBL4933775 | 0.78 | GPR3 (0.41) | GPR3KDM4EMEN1ALDH1A1LMNA | |
| SCHEMBL25472036 | 0.77 | GPR3 (0.40) | GPR3MEN1ALDH1A1LMNAMAPT | |
| SCHEMBL25232450 | 0.77 | GPR3 (0.40) | GPR3MEN1ALDH1A1LMNAMAPT | |
| SCHEMBL14862604 | 0.77 | GRIN2D (0.42) | GPR3ALDH1A1LMNAMAPTL3MBTL1 | |
| SCHEMBL23579547 | 0.77 | GPR3 (0.40) | GPR3MEN1ALDH1A1LMNAMAPT | |
| SCHEMBL14862602 | 0.77 | GRIN2D (0.42) | GPR3ALDH1A1LMNAMAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132536-A1 | PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED | 2008-06-05 | — | — | US | disclosed |
| US-20070111995-A1 | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors | GLAXO GROUP LIMITED (GB) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132536-A1 | PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4C | GPR3 290/4885GABRA1 4095/4885GABRB2 4301/4885 |
| US-20070111995-A1 | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors | PDE4B, PDE3B, PDE4A | GPR3 450/4885GABRA1 2223/4885GABRB2 2028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.